Immuno-oncological (I-O) agents as monotherapy have shown superior efficacy compared to chemotherapy in both first- and second-line setting, with a consistent benefit in overall survival (OS) and a more favourable tolerability profile in high PD-L1 patients.
There are three main reasons why we should discuss immuno-oncological (I-O) agents as monotherapy in non-small cell lung cancer (NSCLC). Firstly, I-O monotherapy has become a standard therapy in the second-line setting. “Some trials comparing an immune checkpoint inhibitor (ICI) as monotherapy with chemotherapy, showed a consistent benefit in OS favouring I-O monotherapy [1,2]”, Prof. Martin Reck (Airway Research Center North, Grosshansdorf, Germany) said at the beginning of his lecture. Furthermore, there is a clear correlation between a biomarker, i.e. PD-L1 expression, and the efficacy of I-O monotherapy. “This correlation is found across all agents we have investigated. In case of pembrolizumab (an...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Electromagnetic Navigation Bronchoscopy Next Article
Molecular Characteristics of SCLC »
Table of Contents: ELCC 2019
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Immunotherapy in Stage 4 Lung Cancer
Trials: Immunotherapy in Stage 4 Lung Cancer
Implementation of Personalised Lung Cancer Care in Clinical Routine
Optimal Management of Brain Metastases in NSCLC
Small Cell Lung Cancer: New Targets
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.